Research Article

ISSN 3069-5503

International Journal of Spine Surgery and Research

The Integration of Artificial Intelligence (AI) in Oncology: Transforming Cancer Care

Nihanthy DS[1]*, Sai Viksheth Raj[2], Mahadev P[3] and Rajath Govind[4]

[1]Consultant-Medical Oncology, Saroj Gupta Cancer Centre & Research centre, Kolkata, India.

[2]Consultant-Spine Oncology, Narayana Health, Kolkata, India.

[3]Senior Consultant & HOD, Radiation Oncology, Apollo Cancer Institute, Chennai, India.

[4]Consultant (Medicine &Medical Oncology), Army Hospital (R&R), New Delhi, India.

[*]Correspondence:
Nihanthy DS, Consultant-Medical Oncology, Saroj Gupta Cancer Centre & Research Centre, Kolkata, India.

Received: 10 Oct 2025; **Accepted:** 11 Nov 2025; **Published:** 28Nov 2025

Citation: Nihanthy DS, Sai Viksheth Raj, Mahadev P, et al. The Integration of Artificial Intelligence (AI) in Oncology: Transforming Cancer Care. Int J Spine Surg Res. 2025; 1(2): 1-6.

ABSTRACT

The advent of artificial intelligence in medical oncology heralds a paradigm shift in cancer diagnosis, treatment, and patient management. AI, particularly through advanced machine learning (ML) algorithms and deep learning techniques, has demonstrated unprecedented capabilities in enhancing precision medicine, revolutionizing diagnostic accuracy, and optimizing therapeutic strategies. By enabling complex data analysis from diverse sources, including medical imaging, genomics, and clinical records, AI is poised to redefine oncological workflows. Its role extends to the discovery of novel biomarkers, predicting treatment response, & personalizing therapeutic interventions, thus offering new frontiers in cancer care.

Despite these advances, several challenges temper the widespread adoption of AI in oncology. The "black-box" nature of many AI models often limits interpretability, leading to hesitancy among clinicians regarding the reliability and transparency of AI-driven decisions. Furthermore, the integration of AI depends heavily on high-quality, representative datasets, which are often siloed across institutions, complicating the potential for widespread implementation. Ethical considerations, including concerns over data privacy, bias in algorithmic decision-making, and the potential erosion of clinician autonomy, underscore the need for a careful and thoughtful approach to AI's integration.

This article delves into the multifaceted role of AI in transforming oncological care, highlighting its vast potential while critically addressing its limitations. By examining the ethical, technical, and practical challenges associated with AI-driven cancer care, we offer a comprehensive evaluation of how AI may reshape the future of oncology. The harmonious convergence of AI's computational prowess with the humanistic aspects of oncology will be pivotal in realizing its full potential.

Keywords
Artificial intelligence (AI), Medical oncology, Machine learning, Deep learning, Precision oncology, Biomarker discovery, Algorithmic bias, Ethical challenges, Personalized cancer care.

Introduction
The rapid advancement of Artificial Intelligence (AI) in healthcare, especially in the field of oncology, marks a pivotal shift in how cancer is diagnosed, treated, and managed. Medical oncology, tasked with combating one of the most complex and heterogeneous diseases, can greatly benefit from AI's capabilities [1,2]. AI's potential to process vast amounts of data, uncover hidden patterns, and assist in decision-making has sparked considerable interest among clinicians, researchers, and policymakers alike. However, while AI promises to revolutionize cancer care, it also brings a range of challenges, including ethical considerations, biases, and concerns about its integration into existing clinical workflows [3-5].

In this article, we explore the comprehensive role of AI in medical oncology, its impact on patient care, the clinical advantages it offers, and the potential pitfalls that need to be addressed for its successful adoption. We will also delve into the future implications of AI, emphasizing the need for a balanced approach to ensure that AI augments, rather than replaces, the irreplaceable human aspects of oncology care [6-8].

Applications of AI in Medical Oncology

Early Detection and Diagnosis: Revolutionizing Cancer Screening

AI has demonstrated immense value in enhancing the accuracy and efficiency of cancer diagnosis, particularly through its integration into radiology, pathology, and molecular diagnostics.

- **Radiological Imaging**: AI-powered image analysis algorithms, especially those based on deep learning (DL), are transforming radiology. AI tools can analyze mammograms, CT scans, MRIs, and PET scans with a level of precision that exceeds traditional methods. For instance, AI can detect microcalcifications or subtle tissue changes in mammograms that may indicate early-stage breast cancer, thus enabling intervention at a curable stage.
- In lung cancer, AI models trained on vast datasets of CT scans have been able to predict the malignancy of lung nodules with higher sensitivity and specificity than radiologists. This reduces the need for invasive biopsies and expedites the decision-making process [9,10].
- **Digital Pathology**: The digitization of histopathological slides has opened doors for AI applications in pathology. Convolutional neural networks (CNNs) can analyze biopsy samples, identifying cancerous cells with unparalleled accuracy. These AI systems are capable of detecting microscopic features such as cellular morphology and nuclear atypia, which might elude the human eye, especially in ambiguous cases. Furthermore, AI can assist in grading tumors and predicting their aggressiveness, aiding pathologists in refining their diagnoses [11].
- **Molecular and Genomic Diagnostics**: AI plays a crucial role in analyzing next-generation sequencing (NGS) data, which is essential for precision oncology. AI algorithms can detect actionable mutations, such as EGFR, ALK, and PIK3CA, and recommend targeted therapies. AI-driven predictive modeling is also helping oncologists anticipate the likelihood of genetic mutations, such as BRCA mutations in breast cancer, without the need for invasive testing, providing a non-invasive method to predict genetic predispositions [4,12].

AI in Treatment Planning: Personalizing Therapy and Optimizing Outcomes

The complexity of cancer treatment has made personalized medicine an essential part of modern oncology. AI can assist oncologists in selecting the most appropriate therapeutic interventions by integrating multiple data streams, including genomics, proteomics, clinical trials, and patient histories.

- **Targeted Therapy and Immunotherapy**: AI enables precision in treatment selection by analyzing a patient's tumor genetic profile, identifying mutations or pathways that are actionable. For example, AI platforms can predict patient responses to immune checkpoint inhibitors by evaluating the tumor microenvironment, PD-L1 expression, and immune infiltrates. This helps personalize immunotherapy, which is notoriously difficult to predict with standard methods [13-15].
- AI can also predict resistance mechanisms to targeted therapies, enabling oncologists to modify treatment regimens before resistance fully develops.
- **Optimizing Chemotherapy**: AI models can analyze past patient data and clinical trials to recommend optimal chemotherapy protocols based on tumor characteristics and patient-specific factors, such as age, comorbidities, and genetic profiles. This reduces the trial-and-error nature of chemotherapy selection and helps in balancing efficacy with potential toxicities [16].
- For example, in Colon cancer, AI tools have been developed to assist in selecting chemotherapy combinations and dosing schedules that maximize therapeutic outcomes while minimizing adverse effects like cardiotoxicity or hematologic toxicity [17].



Figure 1: Application of AI in oncology enhances diagnostic precision through imaging and genomic analysis.



Figure 2: Application of AI in treatment planning, streamlines treatment planning by analyzing patient-specific data, with personalised medicine, targeted therapy and optimising chemotherapy.

Predictive Analytics: Forecasting Prognosis and Toxicities

AI excels in predictive analytics, a field that enables oncologists to better forecast patient outcomes, manage risks, and personalize follow-up care.

- **Prognostication Models**: AI algorithms trained on clinical data, imaging results, and genomic profiles can predict a patient's overall survival (OS) and progression-free survival (PFS) with high accuracy. These models allow oncologists to stratify patients based on their risk profiles, enabling more aggressive treatments for high-risk individuals and more conservative approaches for lower-risk patients [18].
- In diseases such as colorectal cancer or non-small cell lung cancer (NSCLC), where treatment decisions hinge on accurate survival predictions, AI provides a data-driven approach to decision-making.
- **Toxicity Prediction**: One of the major challenges in oncology is managing the toxicities associated with treatment. AI models can predict chemotherapy-induced toxicities, such as febrile neutropenia, cardiotoxicity, or nephrotoxicity, by analyzing patient-specific factors and historical data. This foresight allows for early interventions, such as dose adjustments or pre-emptive measures, reducing treatment-related morbidity and improving patient quality of life [19,20].



Figure 3: AI in predictive Analytics for oncology as prognostic models and for toxicity prediction.

AI in Drug Discovery and Development: Reducing Time and Cost

The process of drug discovery in oncology is notoriously long and expensive, often taking over a decade to bring a new cancer drug to market. AI is significantly accelerating this process by offering innovative solutions in both the discovery and development stages [21].

- **Virtual Drug Screening**: AI can simulate how small molecules or biologics will interact with cancer cells, thus allowing for virtual drug screening of thousands of compounds in a fraction of the time it would take through conventional methods. AI can also identify novel drug targets by analyzing the molecular pathways involved in oncogenesis, which are often too complex for traditional methods to decipher.
- **Drug Repurposing**: AI can mine existing data from clinical trials and patient records to identify off-label uses of approved drugs. This is particularly beneficial in oncology, where time is of the essence, and repurposed drugs can offer immediate clinical utility. For instance, AI has been used to identify metformin, traditionally used for diabetes, as a potential adjuvant therapy in certain cancers.



Figure 4: AI in enhanced drug development process by identifying novel targets, optimizing molecular designs, and predicting clinical outcomes.

Clinical Decision Support Systems (CDSS): Guiding Oncologists Through Complex Cases

AI-powered Clinical Decision Support Systems (CDSS) are designed to provide oncologists with evidence-based treatment recommendations by synthesizing vast amounts of clinical and research data. These systems are particularly useful in complex cases where multiple treatment options exist, or when dealing with rare cancers for which clinical trial data may be limited [22-24].

- **Real-time Decision Making**: By integrating electronic health records (EHRs), clinical trial databases, and molecular diagnostic data, AI-powered CDSS can assist oncologists in making real-time decisions about treatment options. For instance, systems like IBM Watson for Oncology can generate treatment options based on the latest guidelines and research findings, though its efficacy has been questioned and it still requires clinician validation.
- **Clinical Trial Matching**: AI can match cancer patients to suitable clinical trials by analyzing their molecular and clinical data, helping accelerate trial recruitment and offering patients access to cutting-edge therapies.

Patient Monitoring and Follow-up: AI Beyond Treatment

AI's utility in oncology extends beyond diagnosis and treatment, particularly in patient monitoring, follow-up, and survivorship care [25].

- **Wearable Devices**: AI integrated into wearable health devices can monitor vital signs, detect abnormalities, and predict complications in real-time. For instance, AI-powered wearables can track patient temperature, blood pressure, and physical activity during chemotherapy, sending alerts to healthcare providers if signs of toxicity are detected.
- **Remote Monitoring and Telemedicine**: AI can enhance telemedicine platforms by triaging patients, predicting when a patient is likely to relapse, and ensuring timely interventions. This is particularly valuable for oncology patients in remote areas where access to specialized care is limited.



Figure 5: Clinical Decision Support Systems (CDSS): Guiding Oncologists Through Complex Cases. These systems provide personalized recommendations for diagnostics, treatment protocols, and follow-up care, improving decision-making and patient outcomes.



Figure 6: Patient Monitoring and Follow-up by utilizing wearable devices, mobile health applications, AI enables real-time tracking of vital signs, early detection of adverse events, and personalized survivorship plans, ensuring comprehensive long-term care.

Advantages of AI in Medical Oncology

- **Precision and Efficiency**: AI allows for faster and more accurate analyses of vast and complex data, including imaging, genomics, and clinical records, enabling timely and precise cancer diagnoses and treatment recommendations.
- **Reduction in Human Error**: AI acts as a second set of eyes, reducing diagnostic errors that may result from fatigue, oversight, or cognitive biases, particularly in interpreting diagnostic images or pathology results.
- **Tailored Treatment**: By integrating genomic, clinical, and molecular data, AI can facilitate personalized treatment plans, which are particularly beneficial in cancers with variable responses to treatment, such as melanoma or lung cancer.
- **Cost-effectiveness**: In the long run, AI could reduce healthcare costs by improving diagnostic accuracy, optimizing treatment plans, and reducing unnecessary procedures and hospitalizations.
- **Scalability**: AI-driven models can be deployed globally, potentially democratizing access to high-quality oncology care in underserved regions.

Challenges and Disadvantages of AI in Medical Oncology

- **Data Security and Privacy**: The use of sensitive patient data for AI algorithms raises significant concerns regarding privacy and cybersecurity. HIPAA and GDPR compliance must be rigorously enforced.
- **Bias and Inequality**: AI systems can perpetuate biases if trained on non-representative datasets. For example, an algorithm trained predominantly on Caucasian patient data may not perform well on African American or Asian populations, leading to disparities in care.
- **Interpretability**: AI models, particularly deep learning models, often function as "black boxes," making it difficult for oncologists to understand the decision-making process, which can lead to skepticism and hinder adoption.
- **Dependence on High-Quality Data**: AI's effectiveness is contingent upon access to large, high-quality datasets. In oncology, where data is often siloed across institutions, the lack of standardized data sharing poses a significant challenge.

Ethical Considerations in the Use of AI in Oncology

As AI becomes increasingly integrated into oncology care, ethical considerations must be addressed. Ensuring that AI does not replace the human touch in cancer care is paramount, especially as AI's clinical utility continues to evolve.

- **Autonomy**: AI should augment, not replace, clinician judgment. Physicians must retain autonomy in clinical decision-making, using AI as a tool rather than a directive.
- **Informed Consent**: Patients must be fully informed about the role AI plays in their care, including the limitations and potential risks associated with AI-driven recommendations.
- **Accountability**: Clear guidelines must be established to determine accountability in cases where AI contributes to misdiagnoses or adverse outcomes. Both AI developers and clinicians must be held accountable to avoid ethical dilemmas.

Future Directions of AI in Medical Oncology

The future of AI in oncology holds immense promise, with ongoing advancements expected in the following areas:

- **AI and Biomarker Discovery**: AI will continue to play a crucial role in identifying novel biomarkers, particularly in immuno-oncology, where predicting response to checkpoint inhibitors remains challenging.
- **Integrating AI into Multidisciplinary Teams**: AI will increasingly become a key player in tumor boards, where oncologists, pathologists, radiologists, and surgeons collaborate to make treatment decisions. AI-driven tools will provide valuable insights, ensuring that all aspects of a patient's case are considered.
- **AI in Survivorship**: As more patients survive cancer due to improved treatments, AI will be critical in managing long-term follow-up, monitoring for recurrence, and addressing survivorship issues such as chronic pain, fatigue, and psychological well-being.

Ultimately, while AI holds the potential to transform oncology, it is not a panacea. It must be integrated carefully, ethically, and thoughtfully into clinical practice to truly realize its potential. The partnership between AI and human expertise will likely become one of the most significant collaborations in the history of oncology.

Conclusion

AI is poised to revolutionize the field of oncology, offering unparalleled precision, efficiency, and personalization in cancer care. However, the road to full integration is fraught with challenges, ranging from ethical concerns to technical limitations. The key to AI's success in oncology lies in ensuring that it complements rather than replaces the nuanced and empathetic care provided by oncologists. With continued advancements, AI has the potential to not only improve patient outcomes but also to enhance the overall cancer care experience.

References

1. Sebastian AM, Peter D. Artificial Intelligence in Cancer Research: Trends, Challenges and Future Directions. Life. 2022; 12: 1991.
2. Alnuhait MA, Shahbar AN, Alrumaih I, et al. Advancing cancer care: How artificial intelligence is transforming oncology pharmacy. Inform Med Unlocked. 2024; 50: 101529.
3. Wang J, Liu G, Zhou C, et al. Application of artificial intelligence in cancer diagnosis and tumor nanomedicine. Nanoscale. 2024; 16: 14213-14246.
4. Dlamini Z, Francies FZ, Hull R, et al. Artificial intelligence (AI) and big data in cancer and precision oncology. Comput Struct Biotechnol J. 2020; 18: 2300-2311.
5. Luchini C, Pea A, Scarpa A. Artificial intelligence in oncology: current applications and future perspectives. Br J Cancer. 2022; 126: 4-9.
6. Farina E, Nabhen JJ, Dacoregio MI, et al. An overview of artificial intelligence in oncology. Future Sci OA. 2020; 8: FSO787.
7. Senthil Kumar K, Miskovic V, Blasiak A, et al. Artificial Intelligence in Clinical Oncology: From Data to Digital Pathology and Treatment. Am Soc Clin Oncol Educ Book. 2023; 43: e390084.
8. Shreve JT, Khanani SA, Haddad TC. Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical Considerations. Am Soc Clin Oncol Educ Book. 2022; 42: 842-851.
9. Hunter B, Hindocha S, Lee RW. The Role of Artificial Intelligence in Early Cancer Diagnosis. Cancers. 2022; 14: 1524.
10. Hosny A, Parmar C, Quackenbush J, et al. Artificial intelligence in radiology. Nat Rev Cancer. 2018; 18: 500-510.
11. Bera K, Schalper KA, Rimm DL, et al. Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019; 16: 703-715.
12. Dlamini Z, Skepu A, Kim N, et al. AI and precision oncology in clinical cancer genomics: From prevention to targeted cancer therapies-an outcomes based patient care. Inform Med Unlocked. 2022; 31: 100965.
13. Liang G, Fan W, Luo H, et al. The emerging roles of artificial intelligence in cancer drug development and precision therapy. Biomed Pharmacother. 2020; 128: 110255.
14. Chang TG, Cao Y, Sfreddo HJ, et al. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features. Nat Cancer. 2024; 5: 1158-1175.
15. Xu Z, Wang X, Zeng S, et al. Applying artificial intelligence for cancer immunotherapy. Acta Pharm Sin B. 2021; 11: 3393-3405.
16. Froicu EM, Oniciuc OM, Afrăsânie VA, et al. The Use of Artificial Intelligence in Predicting Chemotherapy-Induced Toxicities in Metastatic Colorectal Cancer: A Data-Driven Approach for Personalized Oncology. Diagnostics. 2024; 14: 2074.
17. Park JH, Baek JH, Sym SJ, et al. A data-driven approach to a chemotherapy recommendation model based on deep learning for patients with colorectal cancer in Korea. BMC Med Inform Decis Mak. 2020; 20: 241.
18. Torrente M, Sousa PA, Hernández R, et al. An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study. Cancers. 2022; 14: 4041.
19. Araújo ALD, Moraes MC, Pérez-de-Oliveira ME, et al. Machine learning for the prediction of toxicities from head and neck cancer treatment: A systematic review with meta-analysis. Oral Oncol. 2023; 140: 106386.
20. Farooq M, Shahid MU. Explainable AI and machine learning algorithms to predict treatment failures for patients with cancer. J Clin Oncol. 2023; 41: e13577-e13577.
21. Paul D, Sanap G, Shenoy S, et al. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021; 26: 80-93.

22. Wang L, Chen X, Zhang L, et al. Artificial intelligence in clinical decision support systems for oncology. Int J Med Sci. 2023; 20: 79-86.
23. Shapiro MA, Stuhlmiller TJ, Wasserman A, et al. AI-Augmented Clinical Decision Support in a Patient-Centric Precision Oncology Registry. AI Precis Oncol. 2024; 1: 58-68.
24. Hendriks MP, Jager A, Ebben KCWJ, et al. Clinical decision support systems for multidisciplinary team decision-making in patients with solid cancer: Composition of an implementation model based on a scoping review. Crit Rev Oncol Hematol. 2024; 195: 104267.
25. Liu M. To AI and Beyond. Oncol Issues. 2024; 39: 3.